Ken Carson from Bangor was first diagnosed with optic neuritis in 2001 following a routine eye examination and subsequent ...

The DWP has issued a full list of 533 conditions which could qualify you for a £187 a week payment. Personal Independence ...

Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...

With Kyle Tucker's landmark agreement with the Los Angeles Dodgers, nearly half of USA TODAY Sports' top free agents at the ...

This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.

Oculis Holding (OCS) is back in focus after the U.S. FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging advances, from gene editing and stem cells to microchips and laser-based ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones ...

Eye disease specialist Oculis SA is laying plans to branch out into multiple sclerosis (MS) after the phase II trials of its acute optic neuritis (AON) drug, privosegtor, showed it reduced levels of ...

Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at optic neuritis. Read more here.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial. During the 2025 congress of the European Society ...